Home Tags Polivy

Tag: Polivy

Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse...

Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...

European Regulators Approve Polatuzumab Vedotin, Triggering Milestone Payment for Seattle Genetics

The European Commission's conditional marketing authorization of polatuzumab vedotin (Polivy®; Genentech/Roche) earlier this week triggered a milestone payment which Seattle Genetics will receive from...

Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma

Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of complete response (CR) among patients...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

FDA Grants Accelerated Approval of Polatuzumab Vedotin in Select Patients

The U.S. Food and Drug Administration (FDA) today confirmed that it has granted accelerated approval of polatuzumab vedotin-piiq (Polivy™; Genentech; previously known as DCDS4501A...

X